Pulnovo Medical appoints Edwards Lifesciences veteran as CMO

SHANGHAI - Pulnovo Medical, a company focused on therapies for Pulmonary Hypertension and Heart Failure, announced Monday the appointment of Francis Duhay, MD, MBA, FACS as its Global Chief Medical Officer.

Dr. Duhay, a board-certified General and Cardiothoracic Surgeon, brings over 25 years of experience in clinical medicine, medical device innovation, and executive leadership to the role. He previously served as Chief Medical Officer at Edwards Lifesciences (NYSE:EW), where he contributed to the development and global adoption of Transcatheter Aortic Valve Replacement (TAVR).

During his career, Dr. Duhay has led 88 clinical studies across multiple specialties and worked with regulatory bodies including the U.S. Food and Drug Administration and the Centers for Medicare & Medicaid Services.

The appointment comes as Pulnovo advances its Pulmonary Artery Denervation program and expands into international markets, according to the company’s press release statement.

Pulnovo Medical describes itself as a global leader in mechanism-driven therapies for Pulmonary Hypertension and Heart Failure.

In other recent news, Edwards Lifesciences announced a $500 million accelerated share repurchase program, adding to its year-to-date repurchases, which now exceed $800 million. This move was supported by the company’s existing cash reserves, and it will initially receive approximately 5 million shares. Following this announcement, Leerink Partners raised its price target for Edwards Lifesciences to $85.00, maintaining a Market Perform rating. Similarly, Bernstein SocGen Group increased its price target to $85.00, citing the company’s second-quarter performance that showed a 10.6% organic growth, surpassing consensus estimates by 3%.

Additionally, BTIG upgraded Edwards Lifesciences from Neutral to Buy, setting a price target of $100.00. The upgrade is attributed to the stability observed in the company’s Transcatheter Aortic Valve Replacement (TAVR) segment, which is projected to grow 6-7% year-over-year in 2025. Moody’s Ratings also revised the outlook for Edwards Lifesciences to positive from stable, affirming its Baa2 rating. This reflects expectations that the company will maintain its leadership in medical devices for structural heart diseases while exploring growth opportunities in new areas. These developments highlight the company’s strategic initiatives and positive market sentiment.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.